New MSK research uncovers an unknown role for immune cells in fueling triple-negative breast cancer; identifies a new strategy for fighting leptomeningeal metastases; finds trastuzumab deruxtecan shows enhanced benefit for patients with ERBB2 mutations in breast cancer; shows tumor DNA insights can help guide treatment for patients with hard-to-treat biliary tract cancers; and uses artificial intelligence (AI) to study early development.